Related Experiment Video
Updated: Jun 20, 2026
08:07
Preparation of Herbal Medicine: Er-Xian Decoction and Er-Xian-containing Serum for In Vivo and In Vitro Experiments
Published on: May 31, 2017
Degarelix
James E Frampton1, Katherine A Lyseng-Williamson
1Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
Drugs
|September 15, 2009
Summary
Degarelix rapidly suppresses testosterone and PSA in advanced prostate cancer patients, offering an effective androgen-deprivation therapy. This gonadotropin-releasing hormone (GnRH) antagonist showed faster results than leuprolide without testosterone surges.
Area of Science:
- Oncology
- Pharmacology
- Urology
Background:
- Androgen-deprivation therapy is crucial for advanced prostate cancer.
- Gonadotropin-releasing hormone (GnRH) receptor agonists and antagonists are used for this therapy.
- Degarelix is a GnRH receptor antagonist with a distinct mechanism of action.
Purpose of the Study:
- To evaluate the efficacy and safety of degarelix in patients with advanced prostate cancer.
- To compare the testosterone and prostate-specific antigen (PSA) suppression profiles of degarelix and leuprolide.
- To assess the speed of testosterone and PSA suppression.
Main Methods:
- Randomized, open-label, phase II/III trials involving patients with all stages of prostate cancer.
- Subcutaneous administration of degarelix (240 mg initially, then 80 mg every 28 days).
- Comparison with intramuscular leuprolide (7.5 mg every 28 days).
Main Results:
- Degarelix achieved rapid, profound, and sustained suppression of serum testosterone and PSA.
- Testosterone levels
- PSA suppression was also significantly faster with degarelix.
Conclusions:
- Degarelix is effective and noninferior to leuprolide in maintaining castrate testosterone levels.
- Degarelix offers faster testosterone and PSA suppression compared to leuprolide.
- Degarelix was generally well tolerated, with adverse events mainly related to injection site reactions and hormonal effects.
More Related Videos
Related Concept Videos
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:25Dosage Regimen: Multiple Oral Dosage
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...